Compare Palantir Technologies Inc (PLTR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Palantir Technologies Inc vs Summit Therapeutics Inc — how do they compare? Palantir Technologies Inc trades at $205.86 (market cap $477.68B), while Summit Therapeutics Inc trades at $17.42 (market cap $13.71B). The key difference: Palantir Technologies Inc is far larger — about 34.8× Summit Therapeutics Inc's market cap, and Palantir Technologies Inc is trading nearer its 52-week high, Summit Therapeutics Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Palantir Technologies Inc for 78 Days and Summit Therapeutics Inc for 16 Days on average.
| PLTR | SMMT | |
|---|---|---|
Market Cap | $477.68B | $13.71B |
Volume | 41,744,992 | 6,173,057 |
Sector | Technology | Health |
52-Week High | $207.18 | $26.38 |
52-Week Low | $107.27 | $12.43 |
Typical Hold Time | 78 Days | 16 Days |
Enterprise Value | $468.48B | $13.04B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Palantir (PLTR) trades at $205.71, up 6.01% with strong bullish momentum. The stock shows exceptional fundamental performance with 56.2% revenue growth in 2025 and net income margin expanding to 36.3%. Technical indicators signal bullish sentiment with the price approaching resistance at $206. Recent partnership with Armada for sovereign AI infrastructure and consistent earnings beats highlight the company's growth trajectory.
Palantir presents compelling growth prospects driven by AI platform adoption, though premium valuations (P/E 169.9, P/S 83.02) warrant caution. Analyst consensus remains positive with 54% buy ratings and $191.69 price target. Key risks include valuation sensitivity and competitive pressures in the AI software space. The company's strong cash flow generation and expanding commercial customer base support long-term upside potential.
Summit Therapeutics (SMMT) trades at $17.29, down 3.68% on the day, amid a bullish technical signal driven by moving averages. The company reported no revenue and a net loss of $1.08 billion in 2025, with negative profitability ratios, but recent news of a $2 billion strategic investment from AstraZeneca and expanded clinical collaborations has boosted investor optimism.
The outlook is speculative, with significant upside potential based on the $29.33 analyst consensus price target, but high execution risk remains as the company is pre-revenue and reliant on clinical trial success. Key catalysts include upcoming trial results for ivonescimab, while risks involve drug development setbacks and cash burn.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Palantir Technologies Inc
Palantir Technologies provides organizations with solutions to manage large disparate data sets in an attempt to gain insight and drive operational outcomes. Founded in 2003, Palantir released its Gotham software platform in 2008, which focuses on the government intelligence and defense sectors. Palantir expanded into various commercial markets with its Foundry software platform in 2016 with the intent of becoming the data operating system for companies and industries. The Denver company had 125 customers as of its initial public offering and roughly splits its revenue between commercial and government customers.
Read more on PLTR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
